Literature DB >> 18227703

Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection.

Lutz Kretschmer1, Kai-Martin Thoms, Sabine Peeters, Holger Haenssle, Hans-Peter Bertsch, Steffen Emmert.   

Abstract

For patients with melanoma metastasis to a sentinel lymph node, subsequent complete regional lymph node dissection (CLND) is currently regarded to be the surgical standard. This approach, however, has not been confirmed by controlled studies, so that surgical morbidity is of primary importance. Using clinical examination and a questionnaire, we determined morbidity in 315 patients with axillary or inguinal lymph node excision on whom 275 sentinel lymphonodectomies (SLNEs) and 90 CLNDs were performed. The overall incidence of at least one complication following SLNE was 13.8%. The short-term complication rate was 11.3% (allergic reaction to blue dye 0%, wound breakdown 0%, haematoma 2.5%, wound infection 3.6%, seroma 6.9%). The incidence of long-term complications was 4.1% (persistent tattoo 0.4%, functional deficit 0.4%, nerve dysfunction/pain 0.7% or swelling 2.5%). All complications were mild. Significantly, the complication rate was not higher for patients aged 70 years or older. After CLND, the overall complication rate was significantly higher (65.5%, P<0.000001). The incidence of short-term complications was 50% (haematoma 0%, wound breakdown 6.7%, wound infection 24.7% or seroma 34.8%). The incidence of long-term complications was also 50% (nerve dysfunction/pain 8.9%, functional deficit 16.8%, swelling 37.1%). Overall, inguinal lymph node excision was burdened by a higher complication rate (P=0.015). Age and sex did not influence postoperative morbidity. No deaths linked to either procedure were noted. Complication rates after SLNE are low and most complications are minor and short-lasting. In contrast, CLND has been demonstrated to be a major and potentially morbid surgical procedure. This highlights the importance of testing the therapeutic value that CLND adds to the sentinel lymph node procedure.

Entities:  

Mesh:

Year:  2008        PMID: 18227703     DOI: 10.1097/CMR.0b013e3282f2017d

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  20 in total

1.  Stromal expression of vascular endothelial growth factor C is relevant to predict sentinel lymph node status in melanomas.

Authors:  Elena Gallego; Luis Vicioso; Martina Alvarez; Isabel Hierro; Lidia Pérez-Villa; Alfredo Blanes; Alfredo Matilla
Journal:  Virchows Arch       Date:  2011-01-29       Impact factor: 4.064

2.  Continuous local analgesic therapy reduces pain after radical inguinal/iliacal lymph node dissection.

Authors:  Heiko Neuss; Martin Schomaker; Wieland Raue; Gerold Koplin; Oliver Haase
Journal:  Langenbecks Arch Surg       Date:  2010-12-29       Impact factor: 3.445

3.  Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM.

Authors:  F Egberts; C Hartje; C Schafmayer; K C Kaehler; W von Schönfels; A Hauschild; T Becker; J H Egberts
Journal:  Ann R Coll Surg Engl       Date:  2011-10       Impact factor: 1.891

4.  Is the non-sentinel lymph node compartment the next site for melanoma progression from the sentinel lymph node compartment in the regional nodal basin?

Authors:  Andrei Rios-Cantu; Ying Lu; Victor Melendez-Elizondo; Michael Chen; Alejandra Gutierrez-Range; Niloofar Fadaki; Suresh Thummala; Carla West-Coffee; James Cleaver; Mohammed Kashani-Sabet; Stanley P L Leong
Journal:  Clin Exp Metastasis       Date:  2017-07-11       Impact factor: 5.150

Review 5.  Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.

Authors:  Dale Han; Daniel C Thomas; Jonathan S Zager; Barbara Pockaj; Richard L White; Stanley Pl Leong
Journal:  World J Clin Oncol       Date:  2016-04-10

6.  Dissections of regional lymph nodes for treatment of skin cancer: predicting annual caseloads that will optimise outcomes.

Authors:  J K Dickson; A Davies; S Rahman; C Sethu; J R O Smith; A Orlando; D Ayers
Journal:  Ann R Coll Surg Engl       Date:  2015-01       Impact factor: 1.891

7.  National Practice Patterns in the Management of the Regional Lymph Node Basin After Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma.

Authors:  Cimarron E Sharon; Richard J Straker; Eric H Li; Giorgos C Karakousis; John T Miura
Journal:  Ann Surg Oncol       Date:  2022-08-25       Impact factor: 4.339

8.  Safety of excisional inguinal lymph node biopsies performed for research purposes in HIV-1-infected women and men.

Authors:  Amie L Meditz; Elizabeth Connick; Martin McCarter
Journal:  Surg Infect (Larchmt)       Date:  2014-05-09       Impact factor: 2.150

Review 9.  [Malignant head and neck melanoma: Part 2: Therapy].

Authors:  C Pföhler; T Vogt; C S L Müller
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

10.  Sentinel lymph node biopsy in melanoma: our 8-year clinical experience in a single French institute (2002-2009).

Authors:  Caroline Biver-Dalle; Eve Puzenat; Marc Puyraveau; Delphine Delroeux; Hatem Boulahdour; Frances Sheppard; Fabien Pelletier; Philippe Humbert; François Aubin
Journal:  BMC Dermatol       Date:  2012-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.